Valcyte (Valganciclovir HCl) Patent Expiration, LOE Window & CMS Spending
Valcyte (Valganciclovir HCl) by Cheplapharm Arzneimittel Gmbh: FDA Orange Book LOE 2027-12-11, 8 AB generics, $567K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Cheplapharm Arzneimittel Gmbh |
| FDA Application & Pathway | N022257 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2027-12-11 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 8 |
| 2024 CMS Total Public Spend | $567K |
| 2024 Medicare Part D Spend | $85K |
| 2024 Medicaid Spend | $482K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |